medi-5752
astrazeneca
['nsclc', 'lung', 'sclc', 'medi5752 ', 'medi5752', 'astrazeneca']
 presented the medi5752 efficacy results from a phase i/ii study in first-line non-squamous non-small cell lung cancer (nsclc) at the ongoing 2022 meeting. get our analysts' review: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry